The Diagnostic Efficacy of Glutamine Synthetaseand BCLAF1in Early Diagosis of Hepatocellular Carcinoma in Cirrhotic Patients - Trial NCT06328283
Access comprehensive clinical trial information for NCT06328283 through Pure Global AI's free database. This phase not specified trial is sponsored by Sohag University and is currently Not yet recruiting. The study focuses on Hepatocellular Carcinoma. Target enrollment is 90 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Sohag University
Timeline & Enrollment
N/A
Apr 01, 2024
Mar 01, 2026
Primary Outcome
glutamine synthetase
Summary
Hepatocellular carcinoma (HCC) is the most prominent kind of liver cancer, accounting for 85%
 of primary liver malignancies. It is a very aggressive tumor, having a terrible prognosis and
 poor survival rate HCC is ranked as the sixth most common type of cancer and the third
 leading cause of cancer-related mortalities world wide.
 
 HCC incidences arise in complications associated with chronic liver disease like cirrhosis,
 endemic hepatitis B virus (HBV)/hepatitis C virus (HCV) infections, non alcoholic fatty liver
 disease (NAFLD), and alcohol-related liver disease (Torre, 2015).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06328283
Non-Device Trial